Evidence map›Paper›PMID 41423235›Full record

ArticleNeurologia medico-chirurgica2026

Clazosentan Affects Temporal Profile of Endothelin-A Expression in Macro- and Microcirculation after Subarachnoid Hemorrhage.

Yuyuan Zheng, Masahito Kawabori, Yoichiro Fujioka, Shuho Gotoh, Ryota Tatezawa, Takuma Ikeda, Taishi Honda, Yo Nakahara, Erika Yoshie, Zheng Li and 2 more

Abstract read
In one paragraph

Article in Neurologia medico-chirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuyuan ZhengDepartment of Neurosurgery, Faculty of Medicine, Hokkaido University.
Masahito KawaboriDepartment of Neurosurgery, Faculty of Medicine, Hokkaido University.
Yoichiro FujiokaDepartment of Cell Physiology, Faculty of Medicine, Hokkaido University.
Shuho GotohDepartment of Neurosurgery, Faculty of Medicine, Hokkaido University.
Ryota TatezawaDepartment of Neurosurgery, Faculty of Medicine, Hokkaido University.
Takuma IkedaDepartment of Neurosurgery, Faculty of Medicine, Hokkaido University.
Taishi HondaDepartment of Neurosurgery, Faculty of Medicine, Hokkaido University.
Yo NakaharaDepartment of Neurosurgery, Faculty of Medicine, Hokkaido University.
Erika YoshieDepartment of Neurosurgery, Faculty of Medicine, Hokkaido University.
Zheng LiDepartment of Neurosurgery, Faculty of Medicine, Hokkaido University.
Yusuke OhbaDepartment of Cell Physiology, Faculty of Medicine, Hokkaido University.
Miki FujimuraDepartment of Neurosurgery, Faculty of Medicine, Hokkaido University.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Subarachnoid hemorrhage is a life-threatening cerebrovascular event, and cerebral vasospasm remains a major cause of poor neurological outcomes. Clazosentan, an endothelin-A receptor antagonist, has been recently approved in Japan to reduce post-subarachnoid hemorrhage vasospasm; however, recurrent vasospasm after cessation of therapy has occasionally been reported, which underlying mechanisms remain unclear. Moreover, endothelin-A receptor is also expressed on pericytes; however, the effects of clazosentan on microvascular endothelin-A receptor remain unexplored. In this study, we employed a rat subarachnoid hemorrhage model to investigate the temporal dynamics of vasospasm and endothelin-A receptor expression in both large arteries and microvessels, and to evaluate the effects of clazosentan administration. Sprague-Dawley rats were assigned to naïve controls, subarachnoid hemorrhage with saline, or subarachnoid hemorrhage with continuous clazosentan administration for 7 days via osmotic pumps. Vasospasm was assessed by arterial wall thickness, and endothelin-A receptor expression was quantified using immunohistochemistry and immunofluorescence, including staining with α-SMA, CD31, and PDGF-β. Clazosentan significantly attenuated vasospasm in the middle and anterior cerebral arteries, and recurrent vasospasm was observed 3 days after cessation of clazosentan, coinciding with sustained upregulation of endothelin-A receptor in these vessels. In microvessels, pericyte density transiently decreased, peaking at a nadir on day 3 post-subarachnoid hemorrhage, while endothelin-A receptor expression on pericytes was highest at the same time point, and further elevated by clazosentan treatment. These findings indicate that clazosentan induces endothelin-A receptor upregulation in both macro- and microcirculation, potentially contributing to recurrent vasospasm after treatment, and highlight the critical role of pericytes in post-subarachnoid hemorrhage vascular regulation.

Indexed as

DioxanesEndothelin A Receptor AntagonistsMicrocirculationPyridinesPyrimidinesReceptor, Endothelin ASubarachnoid HemorrhageSulfonamidesTetrazolesVasospasm, IntracranialAnimalsDisease Models, AnimalMaleMicrovesselsRatsRats, Sprague-DawleyclazosentanDioxanesEndothelin A Receptor AntagonistsPyridinesPyrimidinesReceptor, Endothelin ASulfonamidesTetrazolesclazosentanendothelin-A receptorpericytesubarachnoid hemorrhagevasospasm

Identifiers

PMID41423235
PMCPMC12975303

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.